Brief by Shorts91 Newsdesk / 04:00am on 08 May 2024,Wednesday International
AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine, Covishield, citing commercial reasons due to a surplus of updated vaccines. The vaccine, developed with Oxford University, was produced by the Serum Institute of India. Despite admitting to rare side effects, including blood clots and low platelet count, the company denies the withdrawal is linked to a £100 million lawsuit in the UK. AstraZeneca claims the vaccine saved 6.5 million lives in its first year and supplied over three billion doses globally. The company will work with regulators to conclude the withdrawal, as updated vaccines tackle new variants.
